Global Markets
Sanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
